Skip to content
Biodatica
Start free

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Birmingham, Alabama

OncologyCAR-TPhase IIIListed · BMY

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase I trial registered: A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

4d agoTrial registeredJul 16, 2026Source filing (opens the source filing in a new tab)

Momentum

100no change

Momentum 100 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE3 registered

    Aug 29, 2026

    Systemic Sclerosis · RECRUITING · sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis

    ClinicalTrials.gov · NCT07335562 (opens the source filing in a new tab)

  2. Trial

    PHASE2 registered

    Nov 6, 2025

    Lymphoma · RECRUITING · sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

    ClinicalTrials.gov · NCT07015242 (opens the source filing in a new tab)

  3. Trial

    PHASE3 registered

    Mar 12, 2025

    Relapsed or Refractory Multiple Myeloma (RRMM) · RECRUITING · sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

    ClinicalTrials.gov · NCT06615479 (opens the source filing in a new tab)

  4. Trial

    Study registered

    Feb 4, 2025

    Follicular Lymphoma · RECRUITING · sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing Setting

    ClinicalTrials.gov · NCT06794268 (opens the source filing in a new tab)

  5. Trial

    Study registered

    Feb 4, 2025

    Mantle Cell Lymphoma (MCL) · RECRUITING · sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting

    ClinicalTrials.gov · NCT06788652 (opens the source filing in a new tab)

  6. Trial

    Study registered

    Feb 4, 2025

    Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) · RECRUITING · sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting

    ClinicalTrials.gov · NCT06788639 (opens the source filing in a new tab)

  7. Trial

    PHASE1 registered

    Mar 28, 2024

    Multiple Sclerosis, Myasthenia Gravis · RECRUITING · sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)

    ClinicalTrials.gov · NCT06220201 (opens the source filing in a new tab)

  8. Trial

    PHASE2 registered

    Mar 21, 2024

    Multiple Myeloma · RECRUITING · sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

    ClinicalTrials.gov · NCT06297226 (opens the source filing in a new tab)

  9. Trial

    PHASE1 registered

    Feb 22, 2024

    Multiple Myeloma · RECRUITING · sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

    ClinicalTrials.gov · NCT06121843 (opens the source filing in a new tab)

  10. Trial

    PHASE1 registered

    Jan 23, 2024

    Relapsed and/or Refractory Multiple Myeloma · RECRUITING · sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

    ClinicalTrials.gov · NCT06153251 (opens the source filing in a new tab)

  11. Trial

    PHASE1 registered

    Sep 13, 2023

    Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, Systemic Sclerosis, Rheumatoid Arthritis · RECRUITING · sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)

    ClinicalTrials.gov · NCT05869955 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources